Durvalumab (Imfinzi™): First Global Approval – Empower the host – disarm the disease; immune-stimulation brings hope in bladder cancer

Durvalumab (Imfinzi™): First Global Approval – Empower the host – disarm the disease;  immune-stimulation brings hope in bladder cancer

The recent first global approval of durvalumab has been reviewed in detail in the First Global Approval report in Adis’ journal Drugs[1] based on the development milestones tracked in AdisInsight.[2] Continue reading “Durvalumab (Imfinzi™): First Global Approval – Empower the host – disarm the disease; immune-stimulation brings hope in bladder cancer”